PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).
L. G. Paz-Ares
No relevant relationships to disclose
F. De Marinis
Consultant or Advisory Role - Lilly
Honoraria - Lilly
M. Dediu
Consultant or Advisory Role - Lilly
Honoraria - Lilly
M. Thomas
Consultant or Advisory Role - Boehringer Ingelheim; Lilly; Roche
Honoraria - Boehringer Ingelheim; Lilly; Roche
Research Funding - Lilly
J. Pujol
Honoraria - Lilly
P. Bidoli
No relevant relationships to disclose
O. Molinier
No relevant relationships to disclose
T. P. Sahoo
No relevant relationships to disclose
E. Laack
Consultant or Advisory Role - Lilly
Honoraria - Lilly
M. Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Lilly; Merck; Roche
J. Corral
No relevant relationships to disclose
S. A. Melemed
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
W. J. John
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
N. Chouaki
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
A. Zimmerman
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
C. M. Visseren Grul
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
C. Gridelli
No relevant relationships to disclose